ArticleHepatology (Baltimore, Md.)2026

Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).

Zhi-Cheng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.